Mycobacterial infectious disease
MONDO:0020590Infection due to organisms from the genus Mycobacteria.
Also known as: mycobacterial infection, mycobacteriosis, mycobacterium infection
361 clinical trials for this condition and its sub-types, 23 tagged with Mycobacterial infectious disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Mycobacterial infectious disease
-
Tuberculosis 218 trials · 299 incl. sub-types
12 sub-types
- Pulmonary tuberculosis 108 trials · 111 incl. sub-types Sub-types →
- Latent tuberculosis infection 72 trials
- Drug-resistant tuberculosis 9 trials · 40 incl. sub-types Sub-types →
- Extrapulmonary tuberculosis 6 trials · 28 incl. sub-types Sub-types →
- Active tuberculosis 23 trials
- Tuberculous encephalopathy 1 trial
- Endocrine tuberculosis 0 trials Sub-types →
- Multifocal tuberculosis 0 trials
- Primary bone and joint tuberculosis 0 trials
- Primary tuberculosis of the digestive system 0 trials
- Primary tuberculous lymphadenitis 0 trials
- Tuberculoma 0 trials
-
Mycobacterium avium complex disease 22 trials
-
Leprosy 11 trials · 12 incl. sub-types
6 sub-types
- Lepromatous leprosy 3 trials
- Multibacillary leprosy 3 trials
- Borderline leprosy 0 trials
- Indeterminate leprosy 0 trials
- Paucibacillary leprosy 0 trials
- Tuberculoid leprosy 0 trials
-
Buruli ulcer disease 3 trials
-
Mycobacterium xenopi infection 2 trials
-
Aquarium granuloma 0 trials
Most studied deeper sub-types
-
New hope for stubborn lung infection? trial of epetraborole begins, then stops
Disease control Stopped earlyThis study tested an oral drug called epetraborole for people with a tough-to-treat lung infection called MAC lung disease. The trial aimed to see if adding epetraborole to standard treatment could improve symptoms and clear the infection. However, the study was terminated early,…
Phase 2/3 • Sponsor: AN2 Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New inhaled drug aimed at stubborn lung infection shows promise, but trial halted early
Disease control Stopped earlyThis phase 3 study tested an inhaled form of the antibiotic clofazimine added to standard therapy for people with MAC lung disease that did not respond to previous treatment. The goal was to see if the drug could clear the infection from sputum cultures and improve quality of lif…
Phase 3 • Sponsor: Mannkind Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC